Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy

The clinical significance of intraductal carcinoma of the prostate (IDC‐P) in men with nonmetastatic prostate cancer (PCa) treated with high‐dose external‐beam radiation therapy remains unclear. The aim of this study was to evaluate the impact of IDC‐P in men who received intensity‐modulated radiati...

Descripción completa

Detalles Bibliográficos
Autores principales: Aizawa, Rihito, Tsuzuki, Toyonori, Haga, Hironori, Nakamura, Kiyonao, Ogata, Takashi, Inoue, Takahiro, Kobayashi, Takashi, Akamatsu, Shusuke, Goto, Takayuki, Ogawa, Osamu, Mizowaki, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277254/
https://www.ncbi.nlm.nih.gov/pubmed/35514196
http://dx.doi.org/10.1111/cas.15392
_version_ 1784745916815638528
author Aizawa, Rihito
Tsuzuki, Toyonori
Haga, Hironori
Nakamura, Kiyonao
Ogata, Takashi
Inoue, Takahiro
Kobayashi, Takashi
Akamatsu, Shusuke
Goto, Takayuki
Ogawa, Osamu
Mizowaki, Takashi
author_facet Aizawa, Rihito
Tsuzuki, Toyonori
Haga, Hironori
Nakamura, Kiyonao
Ogata, Takashi
Inoue, Takahiro
Kobayashi, Takashi
Akamatsu, Shusuke
Goto, Takayuki
Ogawa, Osamu
Mizowaki, Takashi
author_sort Aizawa, Rihito
collection PubMed
description The clinical significance of intraductal carcinoma of the prostate (IDC‐P) in men with nonmetastatic prostate cancer (PCa) treated with high‐dose external‐beam radiation therapy remains unclear. The aim of this study was to evaluate the impact of IDC‐P in men who received intensity‐modulated radiation therapy (IMRT) for nonmetastatic PCa. All patients with high‐risk (H‐R) and very high–risk (VH‐R) PCa who received IMRT between September 2000 and December 2013 at our institution were analyzed retrospectively. We re‐reviewed biopsy cores for the presence of IDC‐P. Treatment consisted of IMRT (median: 78 Gy at 2 Gy per fraction) plus 6‐month neoadjuvant hormonal therapy (HT). In total, 154 consecutive patients with H‐R and VH‐R PCa were analyzed. Intraductal carcinoma of the prostate was present in 27.9% (n = 43). The median follow‐up period was 8.4 years. The 10‐year PCa‐specific survival, biochemical failure (BF), clinical failure, and castration‐resistant PCa rates were 90.0%, 47.8%, 27.5%, and 24.5% in patients with IDC‐P, and 96.6%, 32.6%, 10.8%, and 7.0% in those without IDC‐P, respectively (p = 0.12, 0.04, 0.0031, and 0.012, respectively). In multivariable analysis, IDC‐P was not identified as an independent predictive factor for BF (p = 0.26). The presence of IDC‐P was correlated with a significantly higher incidence of disease progression in men with H‐R and VH‐R PCa who received IMRT, although it was not identified as an independent predictive factor for BF. Further investigations are needed to determine the significance of IDC‐P as an independent predictive factor for survival outcomes.
format Online
Article
Text
id pubmed-9277254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92772542022-07-15 Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy Aizawa, Rihito Tsuzuki, Toyonori Haga, Hironori Nakamura, Kiyonao Ogata, Takashi Inoue, Takahiro Kobayashi, Takashi Akamatsu, Shusuke Goto, Takayuki Ogawa, Osamu Mizowaki, Takashi Cancer Sci ORIGINAL ARTICLES The clinical significance of intraductal carcinoma of the prostate (IDC‐P) in men with nonmetastatic prostate cancer (PCa) treated with high‐dose external‐beam radiation therapy remains unclear. The aim of this study was to evaluate the impact of IDC‐P in men who received intensity‐modulated radiation therapy (IMRT) for nonmetastatic PCa. All patients with high‐risk (H‐R) and very high–risk (VH‐R) PCa who received IMRT between September 2000 and December 2013 at our institution were analyzed retrospectively. We re‐reviewed biopsy cores for the presence of IDC‐P. Treatment consisted of IMRT (median: 78 Gy at 2 Gy per fraction) plus 6‐month neoadjuvant hormonal therapy (HT). In total, 154 consecutive patients with H‐R and VH‐R PCa were analyzed. Intraductal carcinoma of the prostate was present in 27.9% (n = 43). The median follow‐up period was 8.4 years. The 10‐year PCa‐specific survival, biochemical failure (BF), clinical failure, and castration‐resistant PCa rates were 90.0%, 47.8%, 27.5%, and 24.5% in patients with IDC‐P, and 96.6%, 32.6%, 10.8%, and 7.0% in those without IDC‐P, respectively (p = 0.12, 0.04, 0.0031, and 0.012, respectively). In multivariable analysis, IDC‐P was not identified as an independent predictive factor for BF (p = 0.26). The presence of IDC‐P was correlated with a significantly higher incidence of disease progression in men with H‐R and VH‐R PCa who received IMRT, although it was not identified as an independent predictive factor for BF. Further investigations are needed to determine the significance of IDC‐P as an independent predictive factor for survival outcomes. John Wiley and Sons Inc. 2022-05-19 2022-07 /pmc/articles/PMC9277254/ /pubmed/35514196 http://dx.doi.org/10.1111/cas.15392 Text en © 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle ORIGINAL ARTICLES
Aizawa, Rihito
Tsuzuki, Toyonori
Haga, Hironori
Nakamura, Kiyonao
Ogata, Takashi
Inoue, Takahiro
Kobayashi, Takashi
Akamatsu, Shusuke
Goto, Takayuki
Ogawa, Osamu
Mizowaki, Takashi
Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
title Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
title_full Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
title_fullStr Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
title_full_unstemmed Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
title_short Clinical significance of IDC‐P as predictive factor after intensity‐modulated radiation therapy
title_sort clinical significance of idc‐p as predictive factor after intensity‐modulated radiation therapy
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277254/
https://www.ncbi.nlm.nih.gov/pubmed/35514196
http://dx.doi.org/10.1111/cas.15392
work_keys_str_mv AT aizawarihito clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT tsuzukitoyonori clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT hagahironori clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT nakamurakiyonao clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT ogatatakashi clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT inouetakahiro clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT kobayashitakashi clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT akamatsushusuke clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT gototakayuki clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT ogawaosamu clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy
AT mizowakitakashi clinicalsignificanceofidcpaspredictivefactorafterintensitymodulatedradiationtherapy